Prevention of glucocorticoid-induced osteoporosis

Author： van Brussel MS   Bultink IEM   Lems WF  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.6, 2009-04, pp. : 997-1005

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice

By Walker-Bone Karen   Wood Angela   Hull Richard   Ledingham Joanna M   McCrae Fiona C   Shaban Ragai   Thomas Alastair   Mackay Kirsten  

Clinical Medicine, Vol. 4, Iss. 5, 2004-09 ,pp. : 431-436

Royal College Of Physicians

Access to resources Recommend Favorite

Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis

By Rackoff P.J.  

Drugs & Aging, Vol. 12, Iss. 6, 1998-06 ,pp. : 477-484

Adis International

Access to resources Recommend Favorite

Therapeutic patenting for glucocorticoid-induced osteoporosis

By Cooper M.S.   Stewart P.M.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 6, 2000-06 ,pp. : 847-857

Informa Healthcare

Access to resources Recommend Favorite

Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions

By Bultink Irene EM   Baden Marijke   Lems Willem F  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 2, 2013-02 ,pp. : 185-197

Informa Healthcare

Access to resources Recommend Favorite

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

By Djalali Mahmoud  

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 5, 2013-01 ,pp. : 380-385

NRC Research Press

Access to resources Recommend Favorite